← Back to all trials
Completed
NCT07916350
A Study of the Safety and Effectiveness of a Compound Steep-Pulse Therapy Apparatus for Malignant Liver Tumors
Conditions: Malignant Liver Tumors
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: NA
Enrollment: 181
Sponsor: REMD Medical Technology
Location: Nortion Medical Technology Co., Ltd Shanghai Shanghai Municipality
Summary
This prospective, multicenter, randomized, parallel-group, open-label, noninferiority study compares the safety and efficacy of the Compound Steep-Pulse Therapy Apparatus with radiofrequency ablation in adults with malignant liver tumors. Eligible participants are randomly assigned in a 1:1 ratio to the test group or the control group using a web-based central randomization system, with stratification by tumor diameter and tumor type.
The primary outcome is the ablation success rate at 1 month after treatment, assessed by contrast-enhanced computed tomography or magnetic resonance imaging under blinded conditions. Secondary outcomes include ablation success at 3 months, complete ablation rates, tumor response, local recurrence-free rates, procedure-related complications, console operability, and system stability. Safety is evaluated through adverse events and laboratory assessments.
Eligibility Criteria
Inclusion Criteria:
* 1.Age ≥18 and ≤80 years, regardless of sex.
* 2.Diagnosed with a malignant liver tumor.
* 3.Child-Pugh class A or B liver function.
* 4.A single tumor ≤4 cm in diameter, or up to three tumor lesions, each with a maximum diameter ≤3 cm.
* 5.Willing to participate in the study and voluntarily provide written informed consent.
* 6.Expected survival \>6 months.
Exclusion Criteria:
* 1.Severe dysfunction of major organs, such as the heart, lungs, or kidneys, that, in the investigator's judgment, would preclude tolerance of treatment.
* 2.Contraindications to general anesthesia.
* 3.Allergy to contrast agents used for CT or MRI.
* 4.Previous ablation of the target lesion. Newly developed lesions adjacent to a previously ablated target lesion may be eligible.
* 5.Imaging evidence of invasion of major blood vessels or bile ducts on liver CT, MRI, or other imaging examinations.
* 6.Severe coagulation abnormalities, defined as a platelet count \5 seconds.
* 7.Uncorrectable refractory massive ascites or cachexia.
* 8.Severe portal hypertension or a history of esophageal variceal bleeding within the past month.
* 9.An implanted cardiac pacemaker or a metallic implant within 2.5 cm of the ablation zone.
* 10.A history of epilepsy.
* 11.A history of severe arrhythmia within the past month that could not be controlled with medication.
* 12.Pregnancy, breastfeeding, or plans to conceive during the study.
* 13.Participation in another drug or medical device trial without having exited that trial before enrollment.
* 14.Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this clinical trial.
Source: ClinicalTrials.gov (NCT07916350). StuddyBuddy aggregates publicly available trial information.